# Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment

> **NCT02035345** · PHASE4 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 15 (actual)

## Conditions studied

- Recurrent Ovarian Cancer
- Platinum Sensitive Ovarian Cancer

## Interventions

- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT02035345
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-01
- **Primary completion:** 2015-03
- **Final completion:** 2016-06
- **Target enrollment:** 15 (ACTUAL)
- **Why stopped:** Extended Carboplatin Infusion did not Reduce Frequency of Hypersensitivity Reactions
- **Last updated:** 2016-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035345

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035345, "Slowed Carboplatin Infusion for Ovarian Cancer Patients Receiving Carboplatin Re-Treatment". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02035345. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*